|Awarded On||November 16, 2016|
|Title||Elimination of hypoxia sensitizes resistant solid tumors to immunotherapy|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Michael Curran|
Unfortunately, as they form, cancers evolve means to hide from and locally dampen the immune system allowing them to thrive when they would otherwise be eliminated. In melanoma, we have shown that by blocking key molecules which cancers engage to shut off the immune system, even bulky metastatic tumors can be immunologically rejected. Unlike most therapies for solid tumors, immunotherapy has the potential to effectively cure a patient of all cancer and ward against its return. Despite these dramatic responses in some cancers, metastatic solid tumors such as prostate cancer respond poorly to immunotherapy. Discovering the mechanisms driving the immunotherapy resistance of these tumors an...